Exact Sciences Corp (EXAS) Stock Forecast, Price Targets and Analysts Predictions

EXAS Analyst Ratings

Currently, no data available

Based on NaN analysts giving stock ratings to

Exact

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EXAS Stock 12 Month Forecast

There Are No Analyst Ratings for EXAS In The Last 3 Months.

Highest Price Target―

Average Price Target―

Lowest Price Target―

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

EXAS Financial Forecast

EXAS Earnings Forecast

Next quarter’s earnings estimate for EXAS is -$0.19 with a range of -$0.30 to -$0.10. The previous quarter’s EPS was -$0.45. EXAS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year EXAS has Performed in-line its overall industry.

EXAS Sales Forecast

Next quarter’s sales forecast for EXAS is $848.48M with a range of $831.50M to $865.40M. The previous quarter’s sales results were $878.38M. EXAS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year EXAS has Performed in-line its overall industry.

Detailed List of Analyst Forecasts

Kyle Mikson CFA

Canaccord Genuity

$105

Hold

0.09%

Upside

Reiterated

02/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Beta Bionics, Inc. (NASDAQ: BBNX), Exact Sciences (NASDAQ: EXAS) and Glaukos (NYSE: GKOS)

Subbu Nambi

Guggenheim

―

Hold

―

Reiterated

02/16/26

Analysts Offer Insights on Healthcare Companies: Exact Sciences (NASDAQ: EXAS), HeartFlow, Inc. (NASDAQ: HTFL) and Pelthos Therapeutics (NYSE MKT: PTHS)

Bradley Bowers

Mizuho Securities

$105

Hold

0.09%

Upside

Downgraded

01/20/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilent (NYSE: A), DENTSPLY SIRONA (NASDAQ: XRAY) and Exact Sciences (NASDAQ: EXAS)

Daniel Brennan

TD Cowen

$105

Hold

0.09%

Upside

Reiterated

01/07/26

Patrick B Donnelly

Citi

$105→

Hold

―

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (NASDAQ: CRNX) and Exact Sciences (NASDAQ: EXAS)

Vijay Kumar

Evercore ISI

$105

Hold

0.09%

Upside

Downgraded

01/05/26

Exact Sciences downgraded to In Line from Outperform at Evercore ISIExact Sciences downgraded to In Line from Outperform at Evercore ISI

Daniel Arias

Stifel Nicolaus

$80→$105

Hold

0.09%

Upside

Downgraded

11/28/25

Exact Sciences downgraded to Hold from Buy at StifelExact Sciences downgraded to Hold from Buy at Stifel

William Bonello

Craig-Hallum

$85→$105

Hold

0.09%

Upside

Downgraded

11/24/25

Craig-Hallum downgrades Exact Sciences (EXAS) to a Hold

Tycho Peterson

Jefferies

$105

Hold

0.09%

Upside

Downgraded

11/24/25

Exact Sciences Downgraded to Hold Amid ABT Acquisition and Market Uncertainties

David Westenberg

Piper Sandler

$80→$105

Hold

0.09%

Upside

Downgraded

11/24/25

Exact Sciences downgraded to Neutral from Overweight at Piper SandlerExact Sciences downgraded to Neutral from Overweight at Piper Sandler

Bruce Jackson

Benchmark Co.

―

Hold

―

Downgraded

11/24/25

Exact Sciences downgraded to Hold from Buy at BenchmarkExact Sciences downgraded to Hold from Buy at Benchmark

Brandon Couillard

Wells Fargo

$85→$105

Hold

0.09%

Upside

Downgraded

11/21/25

Exact Sciences downgraded to Equal Weight from Overweight at Wells FargoExact Sciences downgraded to Equal Weight from Overweight at Wells Fargo

Jack Meehan

Nephron

$105

Hold

0.09%

Upside

Downgraded

11/21/25

Exact Sciences downgraded to Hold from Buy at Nephron ResearchExact Sciences downgraded to Hold from Buy at Nephron Research

Luke Sergott

Barclays

$77→$105

Hold

0.09%

Upside

Reiterated

11/21/25

Barclays downgrades Exact Sciences (EXAS) to a Hold

Doug Schenkel

Wolfe Research

―

Hold

―

Downgraded

11/20/25

Exact Sciences downgraded to Peer Perform from Outperform at Wolfe ResearchExact Sciences downgraded to Peer Perform from Outperform at Wolfe Research

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kyle Mikson CFA

Canaccord Genuity

$105

Hold

0.09%

Upside

Reiterated

02/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Beta Bionics, Inc. (NASDAQ: BBNX), Exact Sciences (NASDAQ: EXAS) and Glaukos (NYSE: GKOS)

Subbu Nambi

Guggenheim

―

Hold

―

Reiterated

02/16/26

Analysts Offer Insights on Healthcare Companies: Exact Sciences (NASDAQ: EXAS), HeartFlow, Inc. (NASDAQ: HTFL) and Pelthos Therapeutics (NYSE MKT: PTHS)

Bradley Bowers

Mizuho Securities

$105

Hold

0.09%

Upside

Downgraded

01/20/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilent (NYSE: A), DENTSPLY SIRONA (NASDAQ: XRAY) and Exact Sciences (NASDAQ: EXAS)

Daniel Brennan

TD Cowen

$105

Hold

0.09%

Upside

Reiterated

01/07/26

Patrick B Donnelly

Citi

$105→

Hold

―

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (NASDAQ: CRNX) and Exact Sciences (NASDAQ: EXAS)

Vijay Kumar

Evercore ISI

$105

Hold

0.09%

Upside

Downgraded

01/05/26

Exact Sciences downgraded to In Line from Outperform at Evercore ISIExact Sciences downgraded to In Line from Outperform at Evercore ISI

Daniel Arias

Stifel Nicolaus

$80→$105

Hold

0.09%

Upside

Downgraded

11/28/25

Exact Sciences downgraded to Hold from Buy at StifelExact Sciences downgraded to Hold from Buy at Stifel

William Bonello

Craig-Hallum

$85→$105

Hold

0.09%

Upside

Downgraded

11/24/25

Craig-Hallum downgrades Exact Sciences (EXAS) to a Hold

Tycho Peterson

Jefferies

$105

Hold

0.09%

Upside

Downgraded

11/24/25

Exact Sciences Downgraded to Hold Amid ABT Acquisition and Market Uncertainties

David Westenberg

Piper Sandler

$80→$105

Hold

0.09%

Upside

Downgraded

11/24/25

Exact Sciences downgraded to Neutral from Overweight at Piper SandlerExact Sciences downgraded to Neutral from Overweight at Piper Sandler

Bruce Jackson

Benchmark Co.

―

Hold

―

Downgraded

11/24/25

Exact Sciences downgraded to Hold from Buy at BenchmarkExact Sciences downgraded to Hold from Buy at Benchmark

Brandon Couillard

Wells Fargo

$85→$105

Hold

0.09%

Upside

Downgraded

11/21/25

Exact Sciences downgraded to Equal Weight from Overweight at Wells FargoExact Sciences downgraded to Equal Weight from Overweight at Wells Fargo

Jack Meehan

Nephron

$105

Hold

0.09%

Upside

Downgraded

11/21/25

Exact Sciences downgraded to Hold from Buy at Nephron ResearchExact Sciences downgraded to Hold from Buy at Nephron Research

Luke Sergott

Barclays

$77→$105

Hold

0.09%

Upside

Reiterated

11/21/25

Barclays downgrades Exact Sciences (EXAS) to a Hold

Doug Schenkel

Wolfe Research

―

Hold

―

Downgraded

11/20/25

Exact Sciences downgraded to Peer Perform from Outperform at Wolfe ResearchExact Sciences downgraded to Peer Perform from Outperform at Wolfe Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exact Sciences

3 Months

xxx

Success Rate

4/6 ratings generated profit

Average Return

+9.93%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +9.93% per trade.

1 Year

Eve BursteinBernstein

Success Rate

4/5 ratings generated profit

Average Return

+83.40%

reiterated a buy rating 8 months ago

Copying Eve Burstein's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +83.40% per trade.

2 Years

xxx

Success Rate

10/10 ratings generated profit

Average Return

+93.94%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +93.94% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EXAS Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

2

1

0

Buy

33

31

21

2

1

Hold

42

40

38

10

12

Sell

0

Strong Sell

0

total

77

72

59

12

13

In the current month, EXAS has received 1 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. EXAS average Analyst price target in the past 3 months is ―.

Each month's total comprises the sum of three months' worth of ratings.

EXAS Stock Forecast FAQ

What is EXAS’s average 12-month price target, according to analysts?

Currently, no data Available

What is EXAS’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for EXAS, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EXAS a Buy, Sell or Hold?

Currently, no data Available

What is Exact Sciences Corp’s price target?

Currently, no data Available

What do analysts say about Exact Sciences Corp?

Not enough analysts have published a price target to provide an average price target.

How can I buy shares of EXAS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Exact Sciences (EXAS) Stock Forecast & Price Target

EXAS Analyst Ratings

EXAS Stock 12 Month Forecast

EXAS Financial Forecast

EXAS Earnings Forecast

EXAS Sales Forecast

Detailed List of Analyst Forecasts​

Best Analysts Covering Exact Sciences

EXAS Analyst Recommendation Trends

EXAS Stock Forecast FAQ

Detailed List of Analyst Forecasts